65,437 trials
Prostatic Neoplasms
Primary: Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With…
Dental Pain
Primary: Analysis of Total Pain Relief (TOTPAR) Over 0 to 12 Hours (TOTPAR-12) After Time 0 — 25.868; 31.948; 24.373; 28.549 units on a scale — p=<0.001
Influenza
Primary: Seroconversion — 43; 50; 45; 48 Number of subjects
Bacterial Conjunctivitis
Primary: Clinical Resolution — 89; 62 eyes
Erectile Dysfunction
Primary: Percentage of Participants Who Successfully Operated the Caverject Impulse Delivery System — 95.83 percentage of participants
Carcinoma, Renal Cell
Primary: Overall Survival (OS) — 911.0 Days
PTSD
Primary: Clinician Administered PTSD Scale (CAPS) — 18.6; 9.58 Units on a scale
Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic
Primary: Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54 — 7.76; 7.79; -0.70; -0.62 Percent of glycosylated hemoglobin
Chemotherapy-induced Diarrhea
Primary: Percentage of Participants Developing Diarrhea (Grade 1 to 4) — 76.1; 78.9 Percentage of Participants
Pancreatic Cancer
Primary: Overall Survival (OS) — 6.5; 6.9 Months
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Hepatitis C
Primary: Mean Change in HCV-RNA (Hepatitis C Virus Ribonucleic Acid) Levels From Baseline Through 24 Weeks of Treatment — -0.48; -0.12 log (IU/mL)
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy — 5; 5; 5; 5 mg BID
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) — 30.43; 26.96; 38.85 ng/mL
Alcohol Related Disorders · Alcoholism · Alcohol Abuse
Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28